Mechanisms for the regulation of novel lipids in vivo

体内新型脂质的调节机制

基本信息

  • 批准号:
    10378638
  • 负责人:
  • 金额:
    $ 15.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract: Research: Insulin resistance is a major cause for type 2 Diabetes (T2D) and is implicated in many life- threatening complications of T2D. A better understanding of the molecular mechanisms for insulin resistance is essential to develop potent and safe insulin sensitizers, which could reduce the social and economic burden of metabolic diseases. Our lab discovered a novel class of anti-inflammatory and anti-diabetic lipids, Palmitic Acid Hydroxy Stearic Acids (PAHSAs). PAHSA levels strongly correlate with insulin sensitivity in humans and are down-regulated in adipose tissue (AT) from insulin resistant subjects. PAHSAs are potent hepatic and systemic insulin sensitizers in obese T2D mice. This project will identify the mechanisms for the regulation of PAHSAs in altered metabolic states in vivo and the enzymes mediating their biosynthesis and degradation, providing novel strategies to prevent or treat T2D. Specific Aim1: To determine the mechanisms that regulate PAHSA levels in vivo. Specific Aim2: To identify candidate enzymes for PAHSA biosynthesis and degradation in our unique genetic mouse models of altered glucose homeostasis. Specific Aim3: To identify natural genetic drivers of PAHSA metabolism using the established profiling of the natural genetic variation among 8 mouse strains to mimick human variation. These studies will uncover novel pathways at the crossroad between AT lipogenesis and insulin sensitivity that can be manipulated to prevent or treat T2D. Candidate’s career development plan and career goals: I am highly committed to elucidate the mechanisms for insulin resistance and T2D with the ultimate goal of expanding the therapeutic armamentarium for T2D. During my postdoctoral training in Dr. Barbara’s Kahn lab, I became interested in the connections between AT lipogenesis and systemic insulin sensitivity. During the K01 award, I will acquire the necessary skills to study lipid metabolism in vivo combining innovative and powerful multiomic approaches and molecular biology. The studies in this K01 proposal will be conducted under the mentorship of Drs. Kahn and Saghatelian with the guidance of an outstanding scientific advisory committee (Drs. Alan Attie, Joshua Rabinowitz, and Evan Rosen), who are highly committed to my development into an independent scientist. Periodic meetings with these experts will center on experimental design, discussion of results, future directions, and preparation of R01 and R03 grants. My long-term career goal is to become an NIH-funded independent scientist. The training received during this K01 award is necessary for my successful transition to independent investigator in the Academia. Environment: The BIDMC Endocrine Division is the ideal site for training of young scientists towards a path of independence because it offers unparalleled opportunities for interactions with leaders in the fields of diabetes and metabolism. Graduates from this Division have made transformative discoveries that open new trajectories for diabetes and metabolism research.
项目概要/摘要: 研究:胰岛素抵抗是2型糖尿病(T2 D)的主要原因,并与许多生活相关。 2型糖尿病的危险并发症更好地理解胰岛素抵抗的分子机制是 开发有效和安全的胰岛素增敏剂至关重要,这可以减少社会和经济负担, 代谢性疾病我们的实验室发现了一种新型的抗炎和抗糖尿病的脂质,棕榈酸 羟基硬脂酸(PAHSAs)。PAHSA水平与人类的胰岛素敏感性密切相关, 在来自胰岛素抵抗受试者的脂肪组织(AT)中下调。PAHSAs是强效的肝脏和全身 肥胖T2 D小鼠中的胰岛素增敏剂。该项目将确定在以下方面管制多环芳烃的机制: 改变体内代谢状态和介导其生物合成和降解的酶,提供了新的 预防或治疗T2 D的策略。具体目标1:确定调节PAHSA水平的机制, vivo.具体目标2:在我们独特的方法中鉴定PAHSA生物合成和降解的候选酶 改变葡萄糖稳态的遗传小鼠模型。具体目标3:确定自然遗传驱动因素, PAHSA代谢使用8个小鼠品系之间已建立的天然遗传变异谱, 模仿人类的变异这些研究将揭示AT脂肪生成之间的十字路口的新途径 和胰岛素敏感性,可以被操纵来预防或治疗T2 D。 候选人的职业发展计划和职业目标:我高度致力于阐明机制 用于胰岛素抵抗和T2 D,最终目标是扩展T2 D的治疗设备。期间 我在芭芭拉博士的卡恩实验室的博士后培训,我开始感兴趣的AT之间的联系, 脂肪生成和全身胰岛素敏感性。在K 01奖学金期间,我将获得必要的学习技能 脂质代谢在体内结合创新和强大的多组学方法和分子生物学。的 K 01提案中的研究将在Kahn博士和Saghatelian博士的指导下进行, 一个杰出的科学咨询委员会(艾伦·阿蒂博士,约书亚拉比诺维茨,埃文罗森)的指导, 他们都致力于让我成为一名独立的科学家与这些专家定期举行会议 将集中于实验设计、结果讨论、未来方向以及R 01和R 03的制备 赠款。我的长期职业目标是成为NIH资助的独立科学家。期间接受的培训 这个K 01奖是我成功过渡到学术界独立调查员的必要条件。 环境:BIDMC内分泌部是培养年轻科学家的理想场所, 独立性,因为它提供了与糖尿病领域领导者互动的无与伦比的机会 和新陈代谢。该部门的毕业生取得了变革性的发现,开辟了新的轨迹 用于糖尿病和新陈代谢研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anna Santoro其他文献

Anna Santoro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anna Santoro', 18)}}的其他基金

Mechanisms for the regulation of novel lipids in vivo
体内新型脂质的调节机制
  • 批准号:
    10186875
  • 财政年份:
    2021
  • 资助金额:
    $ 15.07万
  • 项目类别:
Mechanisms for the regulation of novel lipids in vivo
体内新型脂质的调节机制
  • 批准号:
    10614968
  • 财政年份:
    2021
  • 资助金额:
    $ 15.07万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.07万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了